Dr Andrew Kompa
Senior Research Fellow
| telephone | +61 3 9288 3244 |
| facsmilie | +61 3 9288 2581 |
| akompa @ medstv.unimelb.edu.au |
Profile
Dr Andrew Kompa is a Senior Research Officer whose research aims include understanding the mechanisms that lead to the development of cardiovascular disease, in particular cardiac remodelling and heart failure. His research interests involve examining intracellular pathways involved in neurohormonal and cytokine activation in cell culture; using animal models of cardiac disease, to examine the functional, histopathological, molecular and biochemical end points of cardiac remodelling; identifying novel therapeutic targets and strategies for the treatment of these diseases; as well as examining the effectiveness of stem cell therapies. The aims of his research are to identify mechanisms that are involved in the improved outcomes and hence gain a better understanding that will provide clinical benefits for patients with heart disease.
University of Melbourne find an expert profile
Professional Activities:
Member: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), International Society for Heart Research (ISHR).
Journal Referee: British Journal of Pharmacology, Clinical and Experimental Physiology and Pharmacology, Heart Lung Circulation, Naunyn Schmiedeberg's Archives of Pharmacology, Peptides, Life Sciences.
Grant reviewer: National Health and Medical Research Council of Australia, National Heart Foundation of Australia, The Prince Charles Hospital Foundation.
Qualifications
BSc (Hons); GDipDrugEvalPharmSc; PhD
Selected Publications
- Kompa AR, See F, Lewis DA, Adrahtas A, Cantwell DM, Wang B& Krum H. 2008. Long-term but not short-term p38 MAPK inhibition improves cardiac function and reduces cardiac remodeling post-MI. Journal of Pharmacology and Experimental Therapeutics, 325: 741-750.
- Phrommintikul A, Tran L, Kompa AR, Wang BH, Adrahtas A, Cantwell, DM & Krum H. 2008. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction American Journal of Physiology - Heart and Circulation, 294: H1804-1814
- See FCP, Thomas G, Way KJ, Tzanidis A, Kompa A, Lewis D, Itescu S & Krum H. 2004. p38 mitrogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. Journal of the American College of Cardiology. 44 (8): 1679-1689.
- Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A & Krum H. 2004. Differential effect of Urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation. 109: 1212-1214.
- Kompa A, Samuel C & Summers RJ. 2002. Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. British Journal of Pharmacology. 137: 710-718.